.Pharmacolibrary.Drugs.ATC.B.B02BD04 .Pharmacolibrary.Drugs.ATC.B.B02BD04| name: | CoagulationFactorIx | |
| ATC code: | B02BD04 | route: | intravenous |
| compartments: | 2 | |
| dosage: | 50 | mg |
| volume of distribution: | 65 | L |
| clearance: | 3.5 | ml/h/kg |
| other parameters in model implementation | ||
Coagulation factor IX is a plasma glycoprotein essential for the blood coagulation cascade, used in the treatment and prevention of bleeding episodes in patients with hemophilia B (congenital factor IX deficiency). It is an approved medication and available as both plasma-derived and recombinant products.
Pharmacokinetic model in adult male patients with severe hemophilia B after intravenous administration of recombinant factor IX concentrate.
Zhang, Y, et al., & Sidhu, J (2016). Population pharmacokinetics of a new long-acting recombinant coagulation factor IX albumin fusion protein for patients with severe hemophilia B. Journal of thrombosis and haemostasis : JTH 14(11) 2132–2140. DOI:10.1111/jth.13444 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27513989
Nazeef, M, & Sheehan, JP (2016). New developments in the management of moderate-to-severe hemophilia B. Journal of blood medicine 7 27–38. DOI:10.2147/JBM.S81520 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27099538